New to clinical trials? Want to develop your skills in designing and running a randomised trial? Then this course is for you!
I am a 59 year old man who has had Ankylosing Spondylitis from my early twenties and as a result, I was well aware of the risk of taking anti-inflammatory drugs which could cause issues with my stomach and kidneys.
Over the years the numerous blood tests would monitor my kidney function, amongst other things. Nearly three years ago my GP contacted me and asked if I would like to participate in the Barack D trial https://www.phc.ox.ac.uk/phctrials/trial-portfolio/barack-d which was to study people with Chronic Kidney Disease (CKD).
Adlai Harid: Patient Research Ambassador
My name is Adlai Harid and I recently joined the Patient Research Ambassador (PRAI) initiative which I’m very excited to be a part of.
What is ‘Commercial Research’?
This is the term used to describe medical research sponsored and funded by for-profit organisations such as pharmaceutical, medical device and technology companies. These organisations are private companies that can design, collaborate and fund research to be delivered in the NHS.
If it’s ‘for profit’, aren’t patients just guinea pigs being used to make companies more money?
No, in the NHS this really isn’t the case. Any NHS patient who gets involved in medical research, is a volunteer - they are never entered into any NHS research - commercial or non-commercial, without knowing and providing informed consent
A study led by Professor David Osborn in the University College London (UCL) Division of Psychiatry has been published in the Lancet Psychiatry. The study developed a new intervention to reduce cardiovascular disease risk factors for people with severe mental illnesses (SMI), and tested this new intervention against routine General Practice care.
People with SMI, such as schizophrenia, bipolar disorder, or psychosis, have a well-established increased risk of morbidity and mortality from cardiovascular disease. Although the study found similar cardiovascular outcomes in both the Primrose intervention group and routine care, the new intervention was associated with fewer psychiatric admissions and therefore lower costs.
Evidence suggests that large reductions in blood pressure, and too many drug prescriptions may be associated with an increase in serious falls and death in the elderly.
Assessing the safety of reducing medication in older patients (≥80 years) with controlled systolic blood pressure (<150 mmHg), who are receiving ≥2 antihypertensive medications. Systolic blood pressure control at three month follow-up will be compared between those randomly allocated to either removal of one blood pressure medication or usual care.